Physician profile
Harold E Paredes
NPI 1447592969
$52,200.87
in general payments reported to CMS, 2019-2025
13 companies · $429 in 2025
The $429 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $25K · 2021: $260 · 2022: $20.70 · 2023: $416 · 2024: $156 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $50,741.04 | 2019-2025 | Overstitch Endoscopic Suturing System, Exalt Model D, Cre Pro |
| Abbvie INC. | $484.72 | 2019-2025 | |
| Micro-Tech Endoscopy USA, INC. | $296.85 | 2020-2023 | Dat Closure Device, Eus Needle |
| Merck Sharp & Dohme LLC | $200.34 | 2019-2023 | Dificid |
| Cook Medical LLC | $175.67 | 2022-2023 | Echotip |
| Janssen Biotech, INC. | $126.83 | 2021-2024 | Stelara, Tremfya |
| Ardelyx, INC. | $41.49 | 2023-2025 | Ibsrela |
| Pfizer INC. | $29.39 | 2019 | |
| Shire North American Group INC | $24.58 | 2019 | |
| Dova Pharmaceuticals | $23.39 | 2019 | |
| Steris Corporation | $22.47 | 2019 | |
| Celltrion USA INC. | $20.95 | 2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Paredes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.